Gsa Capital Partners LLP X4 Pharmaceuticals, Inc Transaction History

Gsa Capital Partners LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 07, 2025	BUY	$0.28 - $0.82 $214,463 - $628,071	765,941 Added 150.87%	1,273,635 $934,000
Q3 2024 Nov 05, 2024	BUY	$0.54 - $0.86 $274,154 - $436,616	507,694 New	507,694 $340,000
Q1 2024 May 03, 2024	SELL	$0.72 - $1.46 $449,388 - $911,259	-624,150 Reduced 66.04%	321,021 $446,000
Q4 2023 Feb 16, 2024	BUY	$0.61 - $0.99 $197,386 - $320,348	323,584 Added 52.06%	945,171 $793,000
Q3 2023 Nov 15, 2023	BUY	$1.03 - $2.02 $640,234 - $1.26 Million	621,587 New	621,587 $677,000

100

97.9M

500K

20.4K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $233M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.